Tag: exercise

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”

FORM 8.5 (EPT/RI)

MIDDLETOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Orange County Bancorp, Inc. (the “Company” - Nasdaq: OBT), parent company of Orange Bank & Trust Company, (the “Bank”) and Hudson Valley Investment Advisors, Inc. (“HVIA”), today announced that the underwriters for its recently completed public offering have exercised their overallotment option and completed the sale of an additional 258,064 shares of common stock at the public offering price of $23.25 per share. The expected proceeds to the Company in connection with the exercise of the option and the issuance of the additional shares, after deducting the underwriting discount and commissions but before deducting other expenses payable by the Company, are approximately $5.7 million.

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio’s Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company’s common stock with a per share exercise price of $3.03. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

UBISOFT ENTERTAINMENT S.A.